Newly developed retatrutide, a dual -action medication targeting equally GLP-1 and GIP receptors, is sparking considerable excitement within the medical community. Preliminary clinical research have revealed significant decreases in overall mass and gains in physiological markers for individuals with overweight. Experts believe this novel approach